July 22, 2021 – Ortho Clinical Diagnostics (Raritan, NJ) announced its VITROS Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho’s VITROS Critical Care menu, is now available in EU Countries, the U.K. and several ASPAC and LATAM countries.
Results from Ortho’s IL-6 assay can be used to help healthcare teams detect and evaluate inflammatory diseases, including auto-immune disorders, sepsis and cases of severe respiratory infections from COVID-19 and community-acquired pneumonia (CAP) in critically ill patients.
IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress. Ortho’s new IL-6 assay offers earlier detection of inflammation than CRP (c-reactive protein) and is a cost-effective diagnostic complement to PCT (procalcitonin) testing, the company says.
The performance of the VITROS IL-6 test is enhanced by the proprietary technologies and benefits only available on VITROS Systems:
- INTELLICHECK Technology monitors, verifies and documents diagnostic checks throughout sample and assay processing for accurate and efficient reporting.
- MicroSensor Technology provides automatic hemolysis detection-quantitation; helps in managing poor quality samples; reports results faster with confidence by only flagging impacted tests.
- MicroWell Technology combined with our enhanced chemiluminescence detection technology improves signal detection with outstanding precision and wide dynamic range.
- Disposable Tips for samples and reagents avoids risk of false positive results caused by cross contamination.
The IL-6 test can be run on the VITROS XT 7600 and 5600 Integrated systems, and the VITROS 3600 and ECi/ECiQ Immunodiagnostics Systems. Ortho says that the VITROS Systems deliver consistently fast, accurate, reliable results and operational simplicity with the ability to load while running with excellent reagent/calibration stability.